hotspot -WSS

hotspot

author：leisure time 2025-09-06 04:14:48 - browse：537

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： What it’s like to watch children die of measles

Wikipedia

WSS

Just how do doctors, lawmakers, and the public define abortion?

Amylyx ALS drug fails large clinical trial

Headspace, Meta partner to launch VR meditation app for Quest

Just how do doctors, lawmakers, and the public define abortion?

A deep dive into Applied Therapeutics’ data, and questions on Cassava

NEJM study link tiny plastics in blood vessels to heart problems

entertainment

hotspot

focus

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

New air purifier tech could be key to improving indoor air quality

UnitedHealth, Optum discontinue NaviHealth name

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What it’s like to watch children die of measles

Dobbs anniversary: the lost opportunity of abortion as health care

How AI can help patients find reliable information about doctors

Peter Hotez and the public health issue of online harassment

With psoriasis trial ahead, Alumis raises $259 million

hotspot

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Headspace, Meta partner to launch VR meditation app for Quest

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Air quality improving but still lags in Black, Hispanic communities

NEJM study link tiny plastics in blood vessels to heart problems

The problems with dementia villages

focus

Wikipedia

Wikipedia

entertainment